BioSpace News Archive

City of Hope announced that data from an investigational Phase 1/2, single arm trial using a bispecific antibody called mosunetuzumab highlights the paradigm-changing potential of a new treatment option for people with follicular lymphoma, a type of blood cancer and the most common indolent form of non-Hodgkin lymphoma.

Kite, a Gilead Company, announced results from the primary analysis of ZUMA-7, a global Phase 3 study evaluating Yescarta® as a one-time infusion, in a head-to-head study against standard of care for adults with large B-cell lymphoma who relapsed or were refractory to first-line treatment.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with immune system dysfunction, announced new positive efficacy and safety data from the ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, for patients with Waldenström’s macroglobulinemia and confirmed MYD88 and CXCR4 mutations.

Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, presented a trial-in-progress poster for the company’s Phase 1/2 CEDAR trial for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new analyses illustrating responses that first-line treatment with DARZALEX® -based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone.

Three studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition throw a spotlight on novel approaches to screening for and treating blood diseases, as well as an unexpected, potential association between a blood abnormality and Alzheimer’s disease.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced updated positive data from its Phase 1/2 trial of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease despite two or more prior lines of therapy.

Precision BioSciences, Inc., a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion 1 presented at the 63rd American Society of Hematology Annual Meeting.